What is Pulmotect?
Pulmotect is dedicated to pioneering novel treatments for severe respiratory ailments. Its flagship product, PUL-042, is an inhaled therapeutic engineered to bolster the lung's innate immune system, offering protection against a spectrum of pathogens. The company's strategic focus is on safeguarding at-risk populations, including those with COPD, asthma, and individuals undergoing oncological therapies. Ongoing clinical investigations are evaluating PUL-042's efficacy, with the ultimate goal of mitigating respiratory complications and enhancing immune system resilience.
How much funding has Pulmotect raised?
Pulmotect has raised a total of $1.8M across 2 funding rounds:
Series A
$1.8M
Debt
$57K
Series A (2016): $1.8M, investors not publicly disclosed
Debt (2021): $57K led by PPP
What's next for Pulmotect?
The recent influx of substantial expansion capital, categorized as enterprise-level funding, positions Pulmotect for significant scaling and advancement of its therapeutic pipeline. This strategic investment is anticipated to accelerate clinical trial progress for PUL-042 and potentially broaden its application to a wider patient demographic. The company's trajectory suggests a strong emphasis on robust clinical validation and market penetration, aiming to establish PUL-042 as a leading therapeutic intervention in the bio-pharmaceutical landscape for respiratory conditions.
See full Pulmotect company page
